Australia markets open in 7 hours 32 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
747.00+10.77 (+1.46%)
As of 10:28AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 80.08B
Enterprise value 75.76B
Trailing P/E 15.51
Forward P/E 17.45
PEG ratio (5-yr expected) 8.84
Price/sales (ttm)6.08
Price/book (mrq)3.74
Enterprise value/revenue 5.53
Enterprise value/EBITDA 11.82

Trading information

Stock price history

Beta (5Y monthly) 0.20
52-week change 312.50%
S&P500 52-week change 3-13.51%
52-week high 3769.63
52-week low 3538.01
50-day moving average 3728.00
200-day moving average 3659.55

Share statistics

Avg vol (3-month) 3783.46k
Avg vol (10-day) 3537.73k
Shares outstanding 5107.08M
Implied shares outstanding 6N/A
Float 8102.18M
% held by insiders 12.58%
% held by institutions 189.50%
Shares short (14 Nov 2022) 41.76M
Short ratio (14 Nov 2022) 42.38
Short % of float (14 Nov 2022) 41.72%
Short % of shares outstanding (14 Nov 2022) 41.62%
Shares short (prior month 13 Oct 2022) 42.11M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 39.17%
Operating margin (ttm)47.10%

Management effectiveness

Return on assets (ttm)15.72%
Return on equity (ttm)27.76%

Income statement

Revenue (ttm)13.71B
Revenue per share (ttm)128.16
Quarterly revenue growth (yoy)-15.00%
Gross profit (ttm)10.73B
Net income avi to common (ttm)5.37B
Diluted EPS (ttm)47.47
Quarterly earnings growth (yoy)-19.40%

Balance sheet

Total cash (mrq)7.02B
Total cash per share (mrq)65.75
Total debt (mrq)2.7B
Total debt/equity (mrq)12.60
Current ratio (mrq)5.36
Book value per share (mrq)200.93

Cash flow statement

Operating cash flow (ttm)5.67B
Levered free cash flow (ttm)2.94B